{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:06:24Z","timestamp":1773403584101,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Global Research Laboratory","award":["2015045887"],"award-info":[{"award-number":["2015045887"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science, ICT, and Future Planning"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jconrel.2017.04.036","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T17:31:41Z","timestamp":1493314301000},"page":"114-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide"],"prefix":"10.1016","volume":"256","author":[{"given":"Daejin","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyungsu","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukyung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Il","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunghyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6971-586X","authenticated-orcid":false,"given":"Sangyong","family":"Jon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2017.04.036_bb0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncpendmet0017","article-title":"Biologic actions and therapeutic potential of the proglucagon-derived peptides","volume":"1","author":"Drucker","year":"2005","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0010","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/00003495-200767060-00008","article-title":"Exenatide: a review of its use in patients with type 2 diabetes mellitus","volume":"67","author":"Cvetkovic","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1331\/154434506775268698","article-title":"Exenatide: from the Gila monster to the pharmacy","volume":"46","author":"Triplitt","year":"2006","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0020","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0025","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1463-1326.2008.01018.x","article-title":"Exenatide: a review from pharmacology to clinical practice","volume":"11","author":"Gentilella","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1476-5381.2011.01227.x","article-title":"Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity","volume":"163","author":"Gong","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2008.01.015","article-title":"Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration","volume":"356","author":"Gedulin","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0040","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00125-005-0128-9","article-title":"Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs","volume":"49","author":"Simonsen","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0045","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1177\/0091270011413894","volume":"52","author":"Meibohm","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0050","doi-asserted-by":"crossref","first-page":"21969","DOI":"10.1074\/jbc.271.36.21969","article-title":"Long-acting growth hormones produced by conjugation with polyethylene glycol","volume":"271","author":"Clark","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0055","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0060","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/bc990076o","article-title":"Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds","volume":"10","author":"Lee","year":"1999","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0065","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nbt812","article-title":"Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity","volume":"21","author":"Yamamoto","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/bc000082g","article-title":"Rational design of a potent, long-lasting form of interferon: a 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C","volume":"12","author":"Bailon","year":"2001","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0075","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.1588","article-title":"A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner","volume":"27","author":"Schellenberger","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0080","article-title":"GLP2\u20132G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model","volume":"7","author":"Alters","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0085","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nbt1364","article-title":"Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C","volume":"25","author":"Subramanian","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0090","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.2337\/diabetes.53.9.2492","article-title":"A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis","volume":"53","author":"Baggio","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0095","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0049-3848(09)70157-4","article-title":"Half-life extension through albumin fusion technologies","volume":"124","author":"Schulte","year":"2009","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.rinphs.2012.09.001","article-title":"Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes","volume":"2","author":"Selis","year":"2012","journal-title":"Results Pharma. Sci."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0105","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/protein\/gzt048","article-title":"Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer","volume":"26","author":"Podust","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0110","doi-asserted-by":"crossref","first-page":"606","DOI":"10.5483\/BMBRep.2013.46.12.106","article-title":"Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes","volume":"46","author":"Kim","year":"2013","journal-title":"BMB Rep."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087704","article-title":"Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action","volume":"9","author":"Levy","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/bip.22474","article-title":"A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life","volume":"102","author":"Lindgren","year":"2014","journal-title":"Biopolymers"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0165","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1016\/j.bbagen.2013.04.023","article-title":"Albumin as a versatile platform for drug half-life extension","volume":"1830","author":"Sleep","year":"2013","journal-title":"Bba-Gen Subjects"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0125","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/anie.201107894","article-title":"Bio-inspired design and potential biomedical applications of a novel class of high-affinity peptides","volume":"51","author":"Kim","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0130","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1016\/j.biomaterials.2013.12.031","article-title":"VEGF-binding aptides and the inhibition of choroidal and retinal neovascularization","volume":"35","author":"Jo","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0135","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1158\/0008-5472.CAN-13-2187","article-title":"A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling","volume":"74","author":"Kim","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0140","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1039\/c3tb20613k","article-title":"HER2-specific aptide conjugated magneto-nanoclusters for potential breast cancer imaging and therapy","volume":"1","author":"Park","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2014.07.006","article-title":"A high-affinity peptide for nicotinic acetylcholine receptor-\u03b11 and its potential use in pulmonary drug delivery","volume":"192","author":"Park","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0150","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1021\/nl502994y","article-title":"A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins","volume":"14","author":"Choi","year":"2014","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0155","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2008.09.091","article-title":"A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db\/db mice","volume":"133","author":"Jin","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0160","doi-asserted-by":"crossref","first-page":"13188","DOI":"10.1021\/bi010902s","article-title":"Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states","volume":"40","author":"Neidigh","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0170","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1074\/jbc.M109.081828","article-title":"Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding","volume":"36","author":"Andersen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0175","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/19420862.2015.1008345","article-title":"Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs","volume":"7","author":"Roopenian","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.jconrel.2017.04.036_bb0180","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-60761-058-8_6","article-title":"Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies","volume":"602","author":"Roopenian","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2017.04.036_bb0185","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymeth.2013.07.005","article-title":"Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies","volume":"65","author":"Proetzel","year":"2014","journal-title":"Methods"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916309877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916309877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:21:38Z","timestamp":1658967698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916309877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":37,"alternative-id":["S0168365916309877"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.04.036","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}